FAM3C and metastatic neoplasm: Given these distinct lines of evidences, aberrant FAM3C expression is likely to represent a prognostic biomarker for predicting the risk of developing metastatic disease, and opens an opportunity to investigate RalA inhibitors as potential targeted therapies.